We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 17, 2020

Empagliflozin Lowers Risk of Death in Heart Failure

The New England Journal of Medicine

 

Additional Info

The New England Journal of Medicine
Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure
N. Engl. J. Med 2020 Oct 08;383(15)1413-1424, M Packer, SD Anker, J Butler, G Filippatos, SJ Pocock, P Carson, J Januzzi, S Verma, H Tsutsui, M Brueckmann, W Jamal, K Kimura, J Schnee, C Zeller, D Cotton, E Bocchi, M Böhm, DJ Choi, V Chopra, E Chuquiure, N Giannetti, S Janssens, J Zhang, JR Gonzalez Juanatey, S Kaul, HP Brunner-La Rocca, B Merkely, SJ Nicholls, S Perrone, I Pina, P Ponikowski, N Sattar, M Senni, MF Seronde, J Spinar, I Squire, S Taddei, C Wanner, F Zannad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading